Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023)

Arcus Biosciences has reported Accumulated Expenses over the past 7 years, most recently at $15.0 million for Q2 2023.

  • Quarterly results put Accumulated Expenses at $15.0 million for Q2 2023, up 15.9% from a year ago — trailing twelve months through Jun 2023 was $15.0 million (up 15.9% YoY), and the annual figure for FY2022 was $25.0 million, up 47.06%.
  • Accumulated Expenses for Q2 2023 was $15.0 million at Arcus Biosciences, up from $12.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RCUS hit a ceiling of $25.0 million in Q4 2022 and a floor of $2.0 million in Q1 2019.
  • Median Accumulated Expenses over the past 5 years was $9.7 million (2019), compared with a mean of $10.4 million.
  • Peak annual rise in Accumulated Expenses hit 205.29% in 2019, while the deepest fall reached 47.01% in 2019.
  • Arcus Biosciences' Accumulated Expenses stood at $5.0 million in 2019, then soared by 92.79% to $9.5 million in 2020, then surged by 78.14% to $17.0 million in 2021, then surged by 47.06% to $25.0 million in 2022, then tumbled by 40.0% to $15.0 million in 2023.
  • The last three reported values for Accumulated Expenses were $15.0 million (Q2 2023), $12.0 million (Q1 2023), and $25.0 million (Q4 2022) per Business Quant data.